Published in J Neurochem on September 01, 1993
Neuronal degeneration and mitochondrial dysfunction. J Clin Invest (2003) 2.00
Cardioprotection by metabolic shut-down and gradual wake-up. J Mol Cell Cardiol (2009) 1.68
Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet (2009) 1.63
Mitochondrial calcium function and dysfunction in the central nervous system. Biochim Biophys Acta (2009) 1.52
Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci (2008) 1.48
Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci (2013) 1.47
The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels. Basic Res Cardiol (2009) 1.28
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem (2003) 1.20
The mitochondrial permeability transition in neurologic disease. Neurochem Int (2007) 1.19
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet (2010) 1.14
The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov (2012) 1.13
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. Proc Natl Acad Sci U S A (1996) 1.05
Involvement of the up-regulated FoxO1 expression in follicular granulosa cell apoptosis induced by oxidative stress. J Biol Chem (2012) 1.00
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel. Biochim Biophys Acta (2013) 0.99
Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition. Toxicol Sci (2010) 0.99
Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience (2008) 0.99
Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med (2015) 0.95
Cell therapy in Huntington's disease. NeuroRx (2004) 0.94
Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res (2009) 0.92
Response of regional brain glutamate transaminases of rat to aluminum in protein malnutrition. BMC Neurosci (2002) 0.89
The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr (2010) 0.89
Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins. Neurobiol Dis (2009) 0.88
Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia. J Neurosci (2008) 0.87
Mitochondrial matters of the brain: the role in Huntington's disease. J Bioenerg Biomembr (2010) 0.87
Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol (2010) 0.87
Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br J Pharmacol (2004) 0.86
Natural plant products and extracts that reduce immunoexcitotoxicity-associated neurodegeneration and promote repair within the central nervous system. Surg Neurol Int (2012) 0.86
Malonate induces cell death via mitochondrial potential collapse and delayed swelling through an ROS-dependent pathway. Br J Pharmacol (2005) 0.86
The Mammalian Malonyl-CoA Synthetase ACSF3 Is Required for Mitochondrial Protein Malonylation and Metabolic Efficiency. Cell Chem Biol (2017) 0.84
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med (2011) 0.83
Mitochondrial dysfunction in neurodegeneration. J Bioenerg Biomembr (1997) 0.80
MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J Neural Transm (Vienna) (1997) 0.80
Animal models for glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis (2004) 0.79
Electrophysiological actions of felbamate on rat striatal neurones. Br J Pharmacol (1995) 0.79
Key Roles of Glutamine Pathways in Reprogramming the Cancer Metabolism. Oxid Med Cell Longev (2015) 0.79
Both stereoselective (R)- and (S)-1-Methyl-1,2,3,4-tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release. Neurotox Res (2010) 0.79
Acute and long-term response of dopamine nigrostriatal synapses to a single, low-dose episode of 3-nitropropionic acid-mediated chemical hypoxia. Synapse (2010) 0.78
N-methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity. Neurochem Res (2008) 0.78
Dissociated expression of mitochondrial and cytosolic creatine kinases in the human brain: a new perspective on the role of creatine in brain energy metabolism. J Cereb Blood Flow Metab (2013) 0.77
Novel Metabolic Abnormalities in the Tricarboxylic Acid Cycle in Peripheral Cells From Huntington's Disease Patients. PLoS One (2016) 0.75
Oxidative Stress and Huntington's Disease: The Good, The Bad, and The Ugly. J Huntingtons Dis (2016) 0.75
Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. Oxid Med Cell Longev (2015) 0.75
Climate change, human impacts, and the resilience of coral reefs. Science (2003) 19.14
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet (1998) 7.26
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (1984) 6.86
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol (2000) 6.40
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex (1992) 5.57
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology (2002) 4.67
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology (1992) 4.52
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology (2004) 4.00
Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 3.92
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci (1999) 3.85
Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol (1995) 3.60
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol (2000) 2.78
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75
Chronic neurological sequelae to organophosphate pesticide poisoning. Am J Public Health (1994) 2.70
Functional-anatomic correlates of object priming in humans revealed by rapid presentation event-related fMRI. Neuron (1998) 2.61
BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. Proc Natl Acad Sci U S A (1997) 2.53
Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med (1996) 2.43
LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell (1995) 2.37
Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci U S A (1999) 2.36
Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol (1986) 2.33
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol (1999) 2.29
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci (1993) 2.27
Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease. Prog Brain Res (1990) 2.26
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 2.21
Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience (2006) 2.19
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med (1996) 2.14
Synthesis of calf prochymosin (prorennin) in Escherichia coli. Proc Natl Acad Sci U S A (1983) 2.13
Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol (2001) 2.12
Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci (2001) 2.12
Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci (1993) 2.09
Influenza antigenic determinants are expressed from haemagglutinin genes cloned in Escherichia coli. Nature (1980) 2.09
Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem (2007) 2.09
A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol (2001) 2.01
Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J Biol Chem (2000) 2.00
Construction of a genetic map for Caulobacter crescentus. J Bacteriol (1982) 1.99
Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol (2001) 1.96
Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol (1996) 1.91
Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology (1996) 1.89
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet (2001) 1.87
Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 1.87
Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology (2011) 1.83
Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol (1999) 1.81
Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience (2001) 1.80
Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol Assess (2010) 1.79
A comparison of laparascopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer. Gynecol Oncol (2004) 1.76
Miscoding caused by 5-fluorouracil. J Mol Biol (1969) 1.76
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology (2006) 1.73
Isolation and characterization of APLP2 encoding a homologue of the Alzheimer's associated amyloid beta protein precursor. Nat Genet (1993) 1.72
Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem (2000) 1.72
H. M.'s medial temporal lobe lesion: findings from magnetic resonance imaging. J Neurosci (1997) 1.71
Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab (1998) 1.71
Secondary structure of Qbeta RNA. J Theor Biol (1977) 1.68
Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth (2011) 1.67
Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol (1998) 1.67
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol (1996) 1.66
The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. Proc Natl Acad Sci U S A (2000) 1.65
Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry (1991) 1.64
Following the assembly of RNA polymerase-DNA complexes in aqueous solutions with the scanning force microscope. Proc Natl Acad Sci U S A (1994) 1.64
Gastroenteritis viruses: an overview. Novartis Found Symp (2001) 1.63
Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem (1996) 1.61
Changes in the demographics and perioperative care of stage IA(2)/IB(1) cervical cancer over the past 16 years. Gynecol Oncol (2001) 1.61
Rapid sequence analysis of gene trap integrations to generate a resource of insertional mutations in mice. Genome Res (1997) 1.61
Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke (1996) 1.60
Cross-talk among ROR alpha 1 and the Rev-erb family of orphan nuclear receptors. Mol Endocrinol (1994) 1.59
Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. AJNR Am J Neuroradiol (2012) 1.57
Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int (2001) 1.57
Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology (1998) 1.56
Notch1 inhibits neurite outgrowth in postmitotic primary neurons. Neuroscience (1999) 1.54
Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J Neuropathol Exp Neurol (2001) 1.53
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2011) 1.51
Chronic neurologic sequelae to cholinesterase inhibition among agricultural pesticide applicators. Arch Environ Health (1996) 1.51
In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol (2003) 1.50
Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol (1998) 1.47
Pigeonpea genomics initiative (PGI): an international effort to improve crop productivity of pigeonpea (Cajanus cajan L.). Mol Breed (2009) 1.46
Clinical effectiveness of "short" vs "long" psychiatric hospitalization. I. Inpatient results. Arch Gen Psychiatry (1976) 1.44
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol (1999) 1.43
Laparoscopic intracavitary debridement of peripancreatic necrosis: preliminary report and description of the technique. Surgery (2000) 1.42
Prophylactic oophorectomy in Ontario. Fam Cancer (2001) 1.41
Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol (1995) 1.40
Action stat! Alcohol withdrawal syndrome. Nursing (1990) 1.39
A longitudinal study of psychological adjustment to familial genetic risk assessment for ovarian cancer. Gynecol Oncol (1999) 1.38
Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. J Virol (1998) 1.38
Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. J Neurosci (1997) 1.38
Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet (1992) 1.37